Table 4.

Healthcare Personnel Meeting Primary Definition for Pertussis Infection

		Days From Exposure			Acute NP Swab PCR Resultsa			NP Aspirate PCR Resultsc		Anti-PT IgG (EU)		Anti-FHA IgG (EU)
Subject No.	Prophylaxis	Vaccination	Acute Visit	Convalescent Visit	IS481	IS481/ptxs1	Symptoms After the Exposureb	IS481	IS481/ptxs1	Acute	Convalescent	Acute	Convalescent
1	None	−207	13	34	−	ND	None	ND	ND	20	42	112	117
2	None	−397	20	38	−	ND	None	ND	ND	<10	21	37	40
3	None	−125	8	29	−	ND	None	ND	ND	308	242	<10	<10
4	None	−1034	21	39	−	ND	None	ND	ND	125	106	259	256
5	None	−382	7	27	−	ND	Sore throat	−	−	111	67	11	12
6	None	−110	7	36	+	–	None	ND	ND	81	70	ND	ND
7	Azithromycin	−773	8	33	−	ND	Sore throat	+d	−	<10	<10	ND	ND

Abbreviations: EU, enzyme-linked immunosorbent assay units per milliliter; FHA, filamentous hemagglutinin; IgG, immunoglobulin G; ND, not done; NP, nasopharyngeal; PCR, polymerase chain reaction; PT, pertussis toxin; +, positive result; −, negative result.

^aNP swabs tested for PCR only. All convalescent swabs were negative for pertussis by PCR.

^bSubjects were queried daily for 21 days after the exposure was identified for the occurrence of fever, cough, runny nose, and sore throat.

^cNP aspirate was performed only when symptoms occurred during the postexposure monitoring period.

^dCulture for Bordetella pertussis was negative.